Moderna stock was rising early on Monday after the Food and Drug Administration gave limited approval to the company’s newest Covid-19 vaccine. It relieves one worry for the pharmaceutical ...

Experts warn about risks of new COVID-19 vaccine guidelines 04:32. The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for ...

The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above. Moderna expects to have the vaccine available for the 2025-2026 ...

The Food and Drug Administration (FDA) has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for specific high-risk populations, the company announced Saturday. This marks a ...

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12 ...

The case centered on whether Alnylam’s patents, U.S. Patent Nos. 11,246,933 and 11,382,979 were infringed by Moderna’s use of SM-102-a cationic lipid in Moderna’s COVID-19 vaccine formulations.

Moderna said on Friday it has filed a marketing application for the review of its updated COVID-19 vaccine with the U.S. Food and Drug Administration.

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing Covid shot does not currently face.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.